Crossmark

Neuroendocrine neoplasia goes molecular — time for a change

Crossref DOI link: https://doi.org/10.1038/s41571-018-0118-8

Published Online: 2018-11-02

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rindi, Guido https://orcid.org/0000-0003-2996-4404
Wiedenmann, Bertram
License Information

Text and Data Mining valid from 2018-11-02
More Information

Article History

First Online: 2 November 2018

Competing interests

: G.R. has received honoraria from Ipsen and Novartis for his role in their speaker’s bureau. B.W. declares no competing interests.